Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa/IIb study of BL-M09D1 injection in advanced or metastatic urothelial carcinoma and other solid tumors
CTR20263635Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BL-M09D1 in transitional cell carcinoma (TCC) and Nonhematologic neoplasms, sponsored by Biokin Pharmaceutical. Primary endpoints: Recommended phase II dose (RP2D), Treatment-emergent adverse events and treatment-related adverse events and 1 more. Started Oct 2026; status: active.
02
Drugs
BL-M09D1
03
Conditions
transitional cell carcinoma (TCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20263635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263635.